CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
- PMID: 30555890
- PMCID: PMC6280588
- DOI: 10.1016/j.dadm.2018.10.003
CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
Abstract
Introduction: We examined the association between cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, neural novelty responses, and brain volume in predementia old age.
Methods: We conducted a cross-sectional analysis of the observational, multicentric DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) study. Seventy-six participants completed task functional magnetic resonance imaging and provided CSF (40 cognitively unimpaired, 21 experiencing subjective cognitive decline, and 15 with mild cognitive impairment). We assessed the correlation between CSF biomarkers and whole-brain functional magnetic resonance imaging novelty responses to scene images.
Results: Total tau levels were specifically and negatively associated with novelty responses in the right amygdala and right hippocampus. Mediation analyses showed no evidence that these associations were dependent on the volume of hippocampus/amygdala. No relationship was found between phosphorylated-tau or Aβ42 levels and novelty responses.
Discussion: Our data show that CSF levels of total tau are associated with anatomically specific reductions in novelty processing, which cannot be fully explained by atrophy.
Keywords: Alzheimer's disease (AD); Apolipoprotein E (APOE); Aβ42; Cerebrospinal fluid (CSF); Longitudinal; Magnetic resonance imaging (MRI); Mild cognitive impairment (MCI); Positron emission tomography (PET); Subjective cognitive decline (SCD); Tau.
Figures



References
-
- Selkoe D.J. Alzheimer's disease is a synaptic failure. Science. 2002;298:789–791. - PubMed
-
- Holtzman D.M., Goate A., Kelly J., Sperling R. Mapping the road forward in Alzheimer's disease. Sci Transl Med. 2011;3:114ps48. - PubMed
-
- Motter n., Pelfrey V.C., Kholodenko D., Barbour R., Wood J.K., Galasko D. Reduction of amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38:643–648. - PubMed
-
- Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–144. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous